It sounds very positive to me.
iionline.com
"Medical Technology Stock Letter analyst Jim McCamant says that even though anti-angiogenesis is a very competitive market, ImClone's approach is a good one, with a high probability of success. This is due to the intuitive appeal of using a humanized antibody, and because the approach is similar to ImClone's own C225 product, and to Genentech's (NYSE: GNE) highly successful Herceptin."
Theratope clearly falls into this same category. I've read over some of the findings for C225. The results look similar, but I think Theratope has a bigger market at this point (breast vs head/neck). I've owned IMCL several times i like thier product pipe - interesting combinations of treatments. Biomira, on the other hand, specializes specifically in immunogogical therapies, and has considerable experience in this area. C225 and Theratope are both on a similar time track. I think the success of either will reinforce the other.
Angelo, I'm not sure what you take on this is, but I've said many times before that the success of any other small biotech battling cancer will ultimately benefit Biomira.
SM |
